<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7091927/results/search/test_trace/results.xml">
  <result pre="from natural products are described and discussed. Subject terms Viral" exact="infection" post="Drug development Introduction Viral infectious diseases cause significant morbidity"/>
  <result pre="the synthesis of vidarabine (arabinosyladenine), which is used for the" exact="treatment" post="of herpes simplex virus infections. Professor Umezawa and colleagues"/>
  <result pre="Currently, several classes of anti-HIV drugs are available for HIV" exact="treatment" post="and the combination therapies using them, termed highly active"/>
  <result pre="morbidity and mortality. Zidovudine (azidothymidine) was first approved for HIV" exact="treatment" post="by the US Food and Drug Administration in 1987."/>
  <result pre="also exhibited anti-fungal activity, which may be advantageous for the" exact="treatment" post="of AIDS patients with fungal infections. In addition, 14-O-acyladriamycins12"/>
  <result pre="polymerase inhibitors (ribavirin and favipiravir) have been approved for the" exact="treatment" post="of influenza infections. M2 inhibitors 1-Adamantanamine (amantadine) was the"/>
  <result pre="by inhalation. These two drugs are used as a single-dose" exact="treatment" post="for influenza A and B viruses. Virus polymerase inhibitors"/>
  <result pre="coumarins, diarylheptanoids and others.55 HA is also targeted for the" exact="screening" post="of anti-influenza virus drugs. A novel compound with a"/>
  <result pre="adefovir, telbivudine, entecavir and tenofovir), which are useful for therapeutic" exact="treatment" post="to interrupt the disease progression. However, these drug classes"/>
  <result pre="form of a minichromosome that is responsible for persistent HBV" exact="infection" post="and transcribed by host RNA polymerase II to generate"/>
  <result pre="is important to select potential therapeutic targets for chronic HBV" exact="infection" post="from the virus life cycle. Although various anti-HBV drugs,"/>
  <result pre="make reasonable selections of such key targets for the drug" exact="screening" post="for microbial products. Potential applications of microbial products in"/>
  <result pre="that serves as the template for HBsAg expression. To improve" exact="treatment" post="outcomes, novel anti-HBV agents that target other steps of"/>
  <result pre="entities that target HBV DNA synthesis. In general, natural product" exact="screening" post="is a time-consuming process that requires the fractionation and"/>
  <result pre="screening is a time-consuming process that requires the fractionation and" exact="isolation" post="of active compound(s) from complex extracts of an unknown"/>
  <result pre="unknown composition. Recently, we developed a system to facilitate the" exact="detection" post="of the replicating HBV genome using adenovirus vectors,76 which"/>
  <result pre="for studying HBV replication using cell lines. Similarly, new efficient" exact="detection" post="methods for virus replication would allow for the rapid"/>
  <result pre="methods for virus replication would allow for the rapid drug" exact="screening" post="of natural resources. As HBV infection is significantly influenced"/>
  <result pre="for the rapid drug screening of natural resources. As HBV" exact="infection" post="is significantly influenced by various of host factors, host"/>
  <result pre="virion secretion might be a suitable target for anti-HBV drug" exact="screening" post="for microbial metabolites. Furthermore, several therapeutic vaccines for the"/>
  <result pre="screening for microbial metabolites. Furthermore, several therapeutic vaccines for the" exact="treatment" post="of chronic HBV infection are in preclinical and clinical"/>
  <result pre="Furthermore, several therapeutic vaccines for the treatment of chronic HBV" exact="infection" post="are in preclinical and clinical trials. This approach aims"/>
  <result pre="intracellular GTP levels.91 Nucleotide pool imbalances that result from ribavirin" exact="treatment" post="could cause a reduction of viral polymerase activity and"/>
  <result pre="infected cells will help us to accelerate the development of" exact="screening" post="systems and the identification of potential drug targets. We"/>
  <result pre="Antibiot. (Tokyo)198134121912217328061 9HoshinoHSekiJTakeuchiTNew antifungal antibiotics, benanomicins A and B inhibit" exact="infection" post="of T-cell with human immunodeficiency virus (HIV) and syncytium"/>
  <result pre="(Tokyo)198336124212446226635 17DolakLADeBoerCClazamycin B is antibiotic 354J. Antibiot. (Tokyo)19803383847372554 18KoenumaMKinashiHOtakeNAn improved" exact="screening" post="method for antiphage antibiotics and isolation of sarkomycin and"/>
  <result pre="Antibiot. (Tokyo)19803383847372554 18KoenumaMKinashiHOtakeNAn improved screening method for antiphage antibiotics and" exact="isolation" post="of sarkomycin and its relativesJ. Antibiot. (Tokyo)1974278018044457528 19KunimotoTHoriMUmezawaHModes of"/>
  <result pre="Virol.199367468846958392608 25BelovGABidirectional increase in permeability of nuclear envelope upon poliovirus" exact="infection" post="and accompanying alterations of nuclear poresJ. Virol.200478101661017715331749 26UmezawaHAoyagiTMorishimaHMatsuzakiMHamadaMPepstatin, a"/>
  <result pre="derivatives of oxetanocin AJ. Antibiot. (Tokyo)1989426446462722678 68WangXEmerging antivirals for the" exact="treatment" post="of hepatitis BWorld J. Gastroenterol.201420770724976708 69SummersJSmithPMHorwichALHepadnavirus envelope proteins regulate"/>
  <result pre="virus-host interactionsJ. Med. Virol.20148692593224604126 79GriponPCannieIUrbanSEfficient inhibition of hepatitis B virus" exact="infection" post="by acylated peptides derived from the large viral surface"/>
  <result pre="sugar N-butyldeoxynojirimycinProc. Natl Acad. Sci. USA199491223522398134380 84BlockTMTreatment of chronic hepadnavirus" exact="infection" post="in a woodchuck animal model with an inhibitor of"/>
  <result pre="a DNA vaccine for HIV-1Clin. Exp. Immunol.199811130359472658 88WrightPJCrameriGEatonBTRNA synthesis during" exact="infection" post="by Hendra virus: an examination by quantitative real-time PCR"/>
  <result pre="a new broad-spectrum antiviral agentProc. Natl Acad. Sci. USA197370117411784197928 92OestereichLSuccessful" exact="treatment" post="of advanced Ebola virus infection with T-705 (favipiravir) in"/>
  <result pre="Natl Acad. Sci. USA197370117411784197928 92OestereichLSuccessful treatment of advanced Ebola virus" exact="infection" post="with T-705 (favipiravir) in a small animal modelAntiviral Res.2014105172124583123"/>
  <result pre="93SmitherSJPost-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus" exact="infection" post="in a mouse modelAntiviral Res201410415315524462697 94WarrenTKProtection against filovirus diseases"/>
 </snippets>
</snippetsTree>
